医学
脑膜瘤
尿激酶受体
神经外科
放射科
胶质瘤
病变
神经组阅片室
切除术
外科
尿激酶
神经学
癌症研究
精神科
作者
Jane Skjøth‐Rasmussen,Aleena Azam,Carl Christian Larsen,David Scheie,Karina Juhl,Andreas Kjær
标识
DOI:10.1007/s00701-021-05051-3
摘要
Meningiomas are benign lesion although anot insignificant number experiences recurrences despite Simpson grade 1 removal. FG001 is a compound with a fluorophore (ICG) that binds to a urokinase-type plasminogen activator receptor (uPAR) and is currently investigated at our institution in a first-in-human trial. The patient presented with a plausible malignant glioma but proved to be a grade 1 meningioma. FG001 could delineated the tumor not only on the surface but supplementary in the cavity to remove safely the dural attachment. We present FG001 as a new promising tool for improved surgical radicality beyond the intended indication, provided that a prospective validation in a consecutive meningioma cohort demonstrates similar results.
科研通智能强力驱动
Strongly Powered by AbleSci AI